MENU
APR 02, 2020 8:30 AM PDT

Rapid Discovery of Therapeutic Antibodies for SARS-CoV-2 and Other Viral Pandemics

Sponsored by: Berkeley Lights
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Product Manager, Antibody Therapeutics, Berkeley Lights, Inc.
    Biography
      Anupam Singhal earned his PhD from the University of British Columbia and has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto and Stanford University. His work has been cited over 600 times and resulted in several patents for molecular disease diagnosis, antibody discovery, and development of production cell-lines for biologics. At Berkeley Lights, Anupam leads the development of next-generation platforms for the discovery and development of antibody therapeutics.

    Abstract

    Humans are susceptible to many life-threatening viruses such as HIV, influenza and Ebola. The current coronavirus pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020.  Rapid discovery and development of new therapeutics is therefore an absolute necessity to combat these viruses.

    B cells from exposed patients are a potential source of viral neutralizing antibodies. We will demonstrate how B Cell Antibody Discovery on the Beacon® system can be used to rapidly screen human B cells to identify anti-viral antigen-specific antibodies in under a week.  B cells can be screened from both acute and convalescent patients. Our collaborators have already leveraged the speed of our platform to discover >500 antibodies to SARS-CoV-2 in a single day.

    This workflow has the potential to enable rapid discovery of antibodies against difficult therapeutic targets such as SARS-CoV-2 and other viruses.

    Learning Objectives:

    1. Rapid discovery of antibodies against SARS-CoV-2 and other pandemic viruses
    2. Screening of B cells to identify novel therapeutic antibodies
    3. Rapid down-selection of lead candidates

     

     


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources
    Attendees
    • See more